Fred D. Lublin, MD, discusses evolving concepts in MS, including earlier high-efficacy therapy, unrecognized progression, and ...
From a study that analyzed the therapeutic dilemma of treating acute leukemia (AL) during pregnancy and the delicate balance of improving maternal and fetal outcomes, investigators determined that ...
Cardiovascular disease is the leading cause of death in North Carolina, and effective management of the condition is essential to improving residents’ quality of life. Cardiovascular conditions are a ...
The University of Michigan celebrated the 21st anniversary of its annual V-BID Summit on March 11, 2026, highlighting pathways to improve value-based insurance design and ensuring ...
Intranasal epinephrine was developed to provide needle-free, on-demand rescue therapy for CSU flares, addressing limitations of systemic options such as glucocorticoids and their adverse-effect burden ...
AA-IGA and Scalp Hair Assessment PRO stratify severity into five categories, with the PRO enabling patient-centered monitoring and treatment personalization. AASc and ASAMI incorporate extra-scalp ...
Epcoritamab plus R-DHAX/C achieved 79% ORR and 69% CR, with median 1.4 months to response and early activity evident by the first week-6 assessment. Over half of patients reached ASCT after ...
The landscape of cardiology practice in the US is rapidly shifting from physician-owned models toward consolidation, hospital integration, and increasing private equity (PE) investment. Historically, ...
Mock-jury participants favored the plaintiff less often with AI-assisted double reads than with single reads, implying AI workflow design can meaningfully influence perceived radiologist culpability.
This letter refutes the “overdiagnosis” narrative, blaming the stimulant shortage on DEA regulatory failures, clinical constraints, and recognition of historical underdiagnosis. By concluding that ...
Persistence of high EBNA-1 titers across longitudinal samples was characteristic of MS, whereas MOGAD and NMOSD generally exhibited titer attenuation during follow-up. High-level EBNA-1 positivity in ...
Treatment-naïve BRVO eyes showed logMAR BCVA improvement (0.64 to 0.41) alongside CRT reduction (527 µm to 285 µm) over short-term follow-up with SB15. Central RVO eyes improved from logMAR 1.29 to ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results